Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Head & Neck 1

Conditions

Breast Neoplasms 75Neoplasms 15Neoplasm Metastasis 9Advanced Breast Cancer 5Neoplasms by Site 3Breast Diseases 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Patient Compliance 2Ovarian Neoplasms 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Recurrence 1Quality of Life 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1Lethal Congenital Contracture Syndrome 2 1Joint Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1Bone Density 1Arthralgia 1Advanced Metastatic Breast Cancer 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × Anastrozole × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡